Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore FD, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard JC, Huillard O, Rolland F, Houédé N, Spano JP, Demery ME, Vieillot S, L'Haridon T, Hilgers W, Allory Y, Pfister C; VESPER Trial Investigators. Culine S, et al. Among authors: joly f. Clin Genitourin Cancer. 2021 Dec;19(6):554-562. doi: 10.1016/j.clgc.2021.08.005. Epub 2021 Sep 8. Clin Genitourin Cancer. 2021. PMID: 34602349 Clinical Trial.
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Among authors: joly f. Eur Urol. 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28. Eur Urol. 2021. PMID: 32868138 Clinical Trial.
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Culine S, Fléchon A, Gravis G, Roubaud G, Loriot Y, Joly F, Barthélémy P, Assaf E, Mahammedi H, Beuzeboc P, Houédé N, Rolland F, Guillot A, Gross-Goupil M, Spano JP, Tartas S, Deblock M, Chevreau C, Serrate C, Manduzio H, Habibian M, Thézénas S, Allory Y. Culine S, et al. Among authors: joly f. Clin Genitourin Cancer. 2021 Aug;19(4):e216-e222. doi: 10.1016/j.clgc.2021.02.005. Epub 2021 Feb 24. Clin Genitourin Cancer. 2021. PMID: 33753043 Clinical Trial.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L. Rassy E, et al. Among authors: joly f. Clin Genitourin Cancer. 2022 Oct;20(5):488-494. doi: 10.1016/j.clgc.2022.07.003. Epub 2022 Jul 10. Clin Genitourin Cancer. 2022. PMID: 35977881 Clinical Trial.
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
Lagrange JL, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero JM, Joly F, Allouache N, Bachaud JM, Chevreau C, Kramar A, Chauvet B; Study Group on Genito-Urinary Tumors. Lagrange JL, et al. Among authors: joly f. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):172-8. doi: 10.1016/j.ijrobp.2009.10.038. Epub 2010 Apr 10. Int J Radiat Oncol Biol Phys. 2011. PMID: 20385453 Clinical Trial.
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
Culine S, Fléchon A, Guillot A, Le Moulec S, Pouessel D, Rolland F, Ravaud A, Houédé N, Mignot L, Joly F, Oudard S, Gourgou S. Culine S, et al. Among authors: joly f. Eur Urol. 2011 Dec;60(6):1251-7. doi: 10.1016/j.eururo.2011.08.072. Epub 2011 Sep 10. Eur Urol. 2011. PMID: 21924547 Clinical Trial.
Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B. Oudard S, et al. Among authors: joly f. Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607. doi: 10.1016/j.clgc.2016.04.019. Epub 2016 May 2. Clin Genitourin Cancer. 2016. PMID: 27283478
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L. Flippot R, et al. Among authors: joly f. J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13. J Clin Oncol. 2019. PMID: 31194611 Clinical Trial.
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Voog E, Campillo-Gimenez B, Elkouri C, Priou F, Rolland F, Laguerre B, Elhannani C, Merrer J, Pfister C, Sevin E, L'Haridon T, Hasbini A, Moise L, Le Rol A, Malhaire JP, Delva R, Vauléon E, Cojocarasu O, Deguiral P, Cumin I, Cheneau C, Schlürmann F, Delecroix V, Boughalem E, Mollon D, Ligeza-Poisson C, Abadie-Lacourtoisie S, Monpetit E, Chatellier T, Desclos H, Coquan E, Joly F, Tessereau JY, Dupuy S, Déniel Lagadec D, Marhuenda F, Grudé F. Voog E, et al. Among authors: joly f. Int J Cancer. 2020 Mar 15;146(6):1643-1651. doi: 10.1002/ijc.32578. Epub 2019 Aug 1. Int J Cancer. 2020. PMID: 31318983
757 results